Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women

Gynecologic and Obstetric Investigation

Volumn 64, Issue 2, 2007, Pages 61-64

  Saucedo, Renata ^a   Basurto, Lourdes ^a   Zarate, Arturo ^a,b   Martínez, Carlos ^a   Hernandez, Marcelino ^a   Galván, Rosa ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Estradiol therapy; Insulin resistance; Menopause; Plasminogen activator inhibitor 1

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; FOLLITROPIN; GINEDISC 50; GLUCOSE; INSULIN; LUTEINIZING HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYSTERECTOMY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; BLOOD GLUCOSE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; WOMEN'S HEALTH;

EID: 34548090238     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099148     Document Type: Article

References (27)

1. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 1987;69:381-387.
2. Tsikovris JP, Suarez JA, Meyerrose GE: Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002;42:1187-1199.
3. Hamsten A, de Faire U, Walldius G: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9.
4. Lindoff C, Petersson F, Lecander I, Martinsson G, Astedt B: Passage of the menopause is followed by haemostatic changes. Maturitas 1993;17:17-22.
5. Koh KK, Shin MS, Sakuma I: Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:1516-1521.
6. Post MS, van der Mooren MJ, van Baal WM: Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003;189:1221-1227.
7. Lindheim SR, Buchanan TA, Duffy DM, Vijod MA, Kojima T, Stanczyk FZ: Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Invest 1994;1:150-154.
8. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET: Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 2000;23:801-806.
9. Banfi C, Eriksson P, Giandomenico G, Mussoni M, Sironi L, Hamsten A, Tremoli E: Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin. Insights into the signaling pathway. Diabetes 2001;50:1522-1530.
10. Vulin AI, Stanley FM: A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription. J Biol Chem 2002;277:20169-20176.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
12. Martínez C, Basurto L, Zárate A, Saucedo R, Gaminio E, Collazo J: Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005;50:39-43.
13. Padrón ML, Hernández MI, Cervera AR, Ayala AR: Correlación de dos fórmulas para calcular insulinorresistencia. Ginecol Obstet Mex 2001;69:233-238.
14. Scarabin PY, Plu-Bureau G, Bara L: Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993;70:584-587.
15. Thogersen AM, Jansson JH, Boman K, et al: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
16. Taner MZ, Ozpolat E, Taskiran C, et al: Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. Maturitas 2006;53:267-273.
17. Smith LH, Coats SR, Quin H, et al: Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor α and estrogen receptor β in endothelial cells. Circ Res 2004;95:269-275.
18. Seeger H, Wallwiener D, Mueck AO: Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor-1 in human endothelial cell cultures. Climacteric 2001;4:209-214.
19. Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg JS: The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 2000;99:25-34.
20. Gilabert J, Estelles A, Cano A: The effect of estrogen replacement therapy with or without progestagen on the fibrinolytic and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995;173:1849-1854.
21. Lasco A, Alvaro S, Frisina N, Di Benefetto A, Denuzzo G, Cucinotta D: Long-term transdermal estrogen therapy improves lipid profile but not insulin resistance in healthy postmenopausal women. Diabetes Care 2000;23:422-424.
22. Godsland IF, Gangar K, Walton C, et al: Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42: 846-853.
23. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1497.
24. Genest J, Cohn JS: Clustering of cardiovascular risk factors: targeting high risk individuals. Am J Cardiol 1995;76:8A-20A.
25. Wiman B: Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995;74:71-76.
26. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988;60:491-494.
27. Abbasi F, McLaughlin T, Lamendola C, Lipinska I, Tofler G, Reaven G: Comparison of plasminogen activator inhibitor-1 concentration in insulin resistant versus insulin-sensitive healthy women. Arterioscler Thromb 1999;19:2818-2821.